Introduction
About 500-600 million people suffer nodular goiter worldwide, and 4-6% of American adults are goitrous despite normal iodine intake (Freitas, 2000) . Thyrocyte proliferation leading to single nodule or multinodular goiter (MNG), is diagnosed everyday, even in children, and thyroid nodules are detected in more than 50% of autopsies (Mortensen et al., 1955; Derwahl and Studer, 2000) . Malignant thyroid tumors range from relatively benign -occult papillary microcarcinomas found incidentally in up to 24% of the adult population-to rapidly lethal anaplastic carcinomas, frequently resulting in death in less than 6 months (Asa and Ezzat, 2001) . Goiters are currently considered as true benign neoplasms, arising by mechanisms common to all benign tumors. Autoimmune diseases such as Grave's disease can also induce follicular hyperproliferation known as diffuse goiter.
Proliferative thyroid diseases (diffuse goiter, MNG, follicular adenoma, papillary carcinoma, or follicular carcinoma) have unique characteristics compared to other human tumors. Notably, they show a surprisingly low frequency of malignant conversions (given the high incidence of the disease in the normal population) and a very slow growth rate. The very slow growth rates of well-differentiated thyroid carcinomas are independent of the evaluation method used, and in contrast with the much faster growth rates of well-differentiated breast, lung, colon, and stomach adenocarcinomas (Lee et al., 1985; Soares and Sobrinho-Simoes, 1994; Katoh et al., 1995; Sreelekha et al., 2000) . On the other hand, welldifferentiated thyroid carcinomas show little or no apoptosis (Moore et al., 1998; Yoshida et al., 1999; Sreelekha et al., 2000) . However, in spite of the high survival rates of these carcinomas, they metastasize at a high frequency (Chan, 2000) .
Not much is known about the factors influencing progression of normal human thyroid follicular cells to neoplasia and eventual malignancy. Iodine and transforming growth factor-beta (TGF-b) are the only known negative regulators of thyroid cell numbers. To control epithelial cell numbers, TGF-b acts through two independent pathways. First, it inhibits proliferation through Smad-dependent c-myc repression, thus increasing p15 or p21 CKI level, depending on the cell line (reviewed in Chen et al., 2002) . Second, in some cell types TGF-b has been shown to induce apoptosis. The biochemical mechanisms of this apoptotic effect are poorly understood, in part because of the lack of an experimental model allowing separation of cell-cycle arrest from apoptosis. In the rat thyroid follicular cell line FRTL-5, TGF-b has antiproliferative or apoptotic effects depending on the culture conditions (Carneiro et al., 1998) .
TGF-b also has a late tumor-promoting role due to its effects on tumor cell invasion and changes in the tumor microenvironment since it is responsible for the epithelial-mesenchymal transdifferentiation (Derynck et al., 2001; Yang et al., 2002) .
In short-term dispersed cultures of normal human thyroid tissue, TGF-b inhibits growth (Grubeck-Loebenstein et al., 1989) . Thyroid hyperplasias and carcinomas express high levels of TGF-b. This is thought to be a counter-regulatory mechanism to prevent tumor growth (Kimura et al., 1999; Derwahl and Studer, 2002) . In the FMC-133 human thyroid carcinoma line, this growth inhibitory effect of TGF-b is absent, due to p15 and p53 mutations. Based on these data, the current hypothesis for progression from normal thyroid through neoplasia to malignancy is that a mutation creates a thyroid cell that grows faster and responds less to TGF-b. More TGF-b is produced to control thyroid growth, but selection occurs favoring the growth of the unresponsive cells (Asmis et al., 1996; Blaydes and Wynford-Thomas, 1996; Lazzereschi et al., 1997; Goretzki et al. 2000) . This model is, however, in stark contradiction to the pathological data from surgical specimens, which indicate a very low mitotic index.
To investigate the contribution of TGF-b to human thyroid follicular tumor progression, we established phenotypically stable human thyrocyte cultures from different thyroid hyperproliferative pathologies. TGF-b induced cell-cycle arrest in all 20 cultures, but induced apoptosis only in the 17 nonmetastatic cultures. Our data indicate that TGF-b induces apoptosis in normal thyrocytes via p27 reduction, but suggest that in neoplastic thyrocytes this effect is overridden by activation of the NF-kB survival pathway.
Results

Human thyroid cells maintain their phenotype in long-term culture
In total, 19 different thyroid pieces obtained from one normal thyroid (NT), one Grave's Disease (GD), seven multinodular goiters (MNG), two follicular adenomas (FA), four papillary carcinomas (PC), and three lymph node metastasis from PC (M), were sequentially cultured as described in Material and Methods (Figure 1a) . They grew slowly, with doubling time ranging from 35 to 60 h. Two of the thyroid pieces (MNG 1 and MNG 2 ) were obtained from contralateral lobes of the same thyroid. One of the cultures (MNG 6 ) was a single-cell clone isolated from MNG 5 . All cultures maintained expression of thyroid phenotype markers, even in long-term culture. TG was determined by RT-PCR using human-specific primers (Figure 1a) , and by immunofluorescence ( Figure 1b) ; NIS was determined by RT-PCR and by Western blotting using membrane extracts of the cultured thyrocytes, which revealed both the fully glycosylated 111 kDa protein and 80 kDa immature bands (Figure 1c) . We cannot rule out the possibility that long-term cultures became immortalized, but note that telomere length is maintained throughout life in human thyroid follicular cells, through a mechanism independent of telomerase (Matthews et al., 2001; Kammori et al., 2002) .
TGF-b inhibits thyrocyte growth independent of pathological origin
To investigate the contribution of TGF-b to human thyroid follicular tumor progression, we tested the ability of TGF-b to arrest thyrocyte proliferation in growth medium. All cultures showed a highly significant decrease in cell number after 2 or 4 days of culture in growth medium plus 5 ng/ml TGF-b (Figure 2a , and data not shown). TGF-b induced a G 0 /G 1 cell-cycle arrest (Figure 2b ). Similar results were obtained in all passages, even with high passage number. These results are unexpected since it has been reported that proliferation of thyroid carcinoma cells is not inhibited by TGF-b.
We also analysed the expression of TGF-b receptors by Western blotting. Human TRbI had a molecular weight of 45 kDa, larger than the rat receptor. Human TRbII had a molecular weight of 70 kDa, slightly smaller than the rat receptor. Immature nonfully glycosylated forms of both receptors were also detected. These results indicate that all tumors expressed both receptors, although at different levels ( Figure 2c) .
To assess the efficiency of the TGFbR-Smad pathway in the different thyrocytes, we transfected a luciferase expression vector bearing three Smad-responsive elements. All thyrocyte cultures, regardless of pathological origin, responded to TGF-b with a 3-10-fold increase in luciferase expression and the matching Smad2 phosphorylation (Figure 2d ,e).
TGF-b induces apoptosis in all thyrocytes except those from metastatic neoplasms
We next investigated whether TGF-b induced apoptosis. These experiments were performed in deprived medium, since an apoptotic effect of TGF-b in rat thyrocytes in these conditions has already been reported (Carneiro et al., 1998) . TGF-b induced a strong apoptotic response in all cultures derived from the primary tumors, but not in the cultures derived from the metastatic tumors. Apoptosis was detected by staining live cells with annexin-V-FITC or Hoechst 33258 (detecting early and late apoptotic events respectively; Figure 3a 
-induced apoptosis
Thyrocytes from the metastatic tumors did not present apoptosis in response to TGF-b, in spite of the cell-cycle arrest effects of this growth factor in these cells. The precise pathways by which TGF-b induces apoptosis are not known in detail. We thus decided to look for differences between thyrocytes from metastatic and nonmetastatic cultures, that might be related to the difference in apoptosis response. First, we assessed the levels of various cell-cycle-related proteins. Cyclin D1 levels were not affected by TGF-b (Figure 4a ), as was likewise the case with levels of cyclin D3, p21 Cip1 , p130, and Rb (data not shown). Cyclin E levels were slightly increased in some cultures (Figure 4a ). In contrast, levels of the cyclin-dependent kinase inhibitor p27 kip1 were strongly reduced by TGF-b in all cells except those derived from the metastatic tumors (Figure 4a ). This interesting result raises the possibility that p27 may be involved in the apoptotic response to TGF-b.
In some cell systems, p27 is a substrate of the caspase cascades activated during apoptosis induction (Loubat et al., 1999) . The caspase inhibitor z-VAD effectively blocked the apoptotic effect of TGF-b but did not affect the reduction of p27 levels ( Figure 4b ). We thus concluded that the TGF-b-induced p27 reduction is an earlier event than the apoptotic caspase cascade, and may mediate the apoptotic response to TGF-b.
p27 content is markedly increased in all types of quiescent cell, supposedly in order to maintain growth arrest (Millard et al., 1997) . Since p27 inhibits cyclin-cdk complexes and prevents entry into S phase, we assessed whether the reduction of p27 after TGF-b addition enables S-phase onset. Cdk2 activity was increased by TGF-b in all thyrocytes except those from the metastatic cultures (Figure 4c) . Furthermore, TGF-b progressively and significantly increased bromodeoxyuridine uptake, despite the fact that the experiment was performed in deprived medium ( Figure 4d ,e); no effect on bromodeoxyuridine uptake was observed in the metastatic cultures (Figure 4e ,M). Our next question was whether Cdk2 activation is a necessary step for the cell to enter (Figure 4f ). We thus propose that TGF-b reduces p27 'security levels', facilitating entry into the cell cycle when cells should otherwise not enter it, thus provoking apoptosis. If this hypothesis is correct, p27 reduction may be the main pathway of TGF-b-induced apoptosis. In the absence of any treatment, expression of the antisense p27 induced apoptosis in all types of culture, including the metastatic (Figure 5a ). This effect was blocked by the Cdk2 inhibitor roscovitine (Figure 5b) .
Additionally, we used a reverse approach. Overexpression of Flag-p27 prevented the apoptotic effect of TGF-b in all thyroid cultures studied (Figure 5c ), thus confirming the importance of high p27 levels for survival in deprived conditions. However, we also obtained an unexpected result: in cultures of cells overexpressing p27, cell number after TGF-b treatment was in fact higher than in mock-transfected cultures (Figure 5d ). This suggests that TGF-b favors survival if p27 levels are not decreased.
TGF-b induces the NF-kB survival pathway
This last result suggests that TGF-b is a 'double agent', potentially inducing either apoptosis or survival. Since it has been reported that in colon carcinoma cells, NF-kB activation protects against apoptosis (Barkett and Gilmore, 1999) , the NF-kB pathway is one of the main pathways related to cell survival. NF-kB is a TGF-b induces apoptosis and survival in human thyrocytes SB Bravo et al transcription factor known to be sequestered in the cytoplasm through binding to the inhibitor IkB. After activation, IkB is ubiquitinated and degraded. Released NF-kB complexes go to the nuclei, where they act as transactivating factors. To our knowledge, there have been no previous reports of NF-kB activation after TGF-b treatment. However, all of our pathological thyrocyte cultures showed a marked decrease in IkBa levels after 24 h of TGF-b treatment, whereas normal thyrocytes showed an increase (Figure 6a) . In normal cells after NF-kB activation, a positive feedback process has been described in which NF-kB-activated complexes strongly transactivate the IkBa gene, thus returning to the basal state (de Martin et al., 1993) . To assess the functionality of the NF-kB pathway, we transfected our thyroid cultures with a vector bearing three tandemrepeated kB motifs. All of the tumor thyrocytes showed a marked increase in NF-kB activation (Figure 6b ), except MNG 8 . Normal thyrocytes showed significant but very slight activation in agreement with the Western blot results for IkB. We also investigated whether SN50, a cell-permeant peptide direct inhibitor of NF-kB (Lin et al., 1995) , had any effect on apoptosis in deprived medium. We observed a clear potentiation of TGF-binduced apoptosis when SN50 was present, confirming that the survival effect of TGF-b is mediated by the NFkB pathway (Figure 6c ,e left).
In our cultures, we did not detect differences in TGF-binduced apoptosis between the neoplastic (PC, FA) cultures and the normal or hyperplastic cultures (NT, GD, MNG) (Figure 3) . However, these experiments were performed in deprived medium: it is possible that in more realistic settings, the apoptotic effect of TGF-b is compensated by other biological molecules revealing subtle differences in normal vs pathological thyrocytes. We thus performed analogous assays in growth medium (i.e. medium containing numerous growth factors, including TSH, insulin, and diverse factors present in calf serum). As seen in Figure 6d , in the NT and some MNG cultures, there was a small but significant increase in apoptosis after adding TGF-b to the growth medium, in spite of the numerous other survival factors present. However, in other MNG cultures, as well as FA and PC cultures, addition of TGF-b to the growth medium did not alter the basal apoptotic levels (Figure 6d ). We next investigated whether this lack of apoptotic response to TGF-b is maintained in the presence of SN50, which blocks the migration of NF-kB into the nucleus. Results are shown for one of the PC cultures. When SN50 was present in the deprived medium (Figure 6e, left) , TGF-binduced apoptosis was markedly enhanced, as seen in Figure 6c . Furthermore, in the PC culture, the lack of apoptotic response to TGF-b in growth medium was not maintained in the presence of SN50 (Figure 6e, right) .
Discussion
TGF-b is one of the main factors controlling epithelial and hematopoietic cell number. It has two effects: inhibition of cell-cycle progression and induction of apoptosis. However, in later-stage cancer cells, TGF-b is a promoter of tumor progression and invasion. Little is known about the signaling mechanisms that allow TGFb to induce apoptosis, and how these mechanisms may be bypassed in tumor cells. Moreover, these mechanisms appear to differ depending on the type and state of the cell to which TGF-b binds (Derynck et al., 2001) . Thus, the development and standardization of models simulating human pathophysiological conditions 'in vivo' becomes essential for investigation of the biology of this factor.
In this study, we established human thyrocyte primary cultures from thyroid specimens obtained from a range of pathologies commonly submitted to surgery. All of these cells maintained their phenotype, and thus, serve as models for studying effects of TGF-b in the thyroid, and its putative role in the progression to neoplasia and eventual malignancy. Independently of the original pathology, TGF-b maintained its cell-cycle arrest effect in all cultures. However, the apoptotic effect of TGF-b was maintained only in nonmetastatic thyroid, not in metastatic thyroid.
We demonstrated that the TGF-b-induced apoptosis in human thyrocytes is absolutely dependent on p27 kip1 reduction. Several lines of evidence confirm this conclusion. First, TGF-b induced a marked reduction in p27 levels in all thyrocyte cultures showing apoptosis. Second, apoptosis was dependent on Cdk2 activation and S-phase onset, since TGF-b-induced apoptosis was blocked by roscovitine. Third, the reduction of p27 levels with antisense p27, in the absence of any other treatment, drove cells to apoptosis, likewise blocked by roscovitine. Conversely, maintaining p27 levels in the presence of TGF-b eliminated apoptosis. It seems that p27 levels are raised in quiescent thyrocytes as an 'insurance policy' to prevent death. The relationship between p27 and apoptosis is unclear and controversial in the literature. p27À/Àmurine cells show strikingly high levels of apoptosis (Hiromura et al., 1999) . However, melanoma cells with high p27 levels have been reported to show increased apoptosis (D'Agnano et al., 2001) . AS-p27 oligonucleotides have a synergistic antitumor effect with chemotherapy in mice (Achenbach et al., 2000) , and p27 induces resistance to cytotoxicdrug-induced apoptosis in leukemia cells (Eymin et al., 1999) . Immunohistochemically determined p27 levels in diverse types of human tumor (including thyroid tumors) correlate inversely with the degree of malignancy (Khoo et al., 2002) . However, a paradoxically high expression of p27 is observed in the most aggressive or metastatic tumors (reviewed in Sgambato et al., 2000) .
To date, several TGF-b-induced late events leading to apoptosis have been described, including induction of oxidative stress, downregulation of Bcl-2, and activation of caspase 3 or the mitochondrial septin ARTS (reviewed in Jang et al., 2002) . However, the initial events that follow receptor activation and lead to cell death are not understood. It has been suggested that apoptosis may be initiated by Daxx adaptor protein (Perlman et al., 2001) or by a Smaddependent DAP-kinase increase (Jang et al., 2002) . Our data indicate a downstream mechanism initiating S phase before apoptosis. It has been postulated that nuclear apoptotic events are dependent on Cdk2 (Harvey et al., 2000) .
Another important finding of the present study was the survival effect of TGF-b on thyrocytes when p27 levels were maintained. This effect may be mediated by activation of NF-kB by TGF-b. In normal thyrocytes, TGF-b-stimulated NF-kB activation was tightly regulated, but in hyperplastic thyrocytes it seems to be activated for a longer time. In fact, blocking this pathway nearly duplicated TGF-b-induced apoptosis in deprived medium and rescued TGF-b-dependent apoptosis in carcinoma cells in spite of the growth medium. To our knowledge, this is the first evidence linking TGF-b survival effects to NF-kB signal transduction pathway in human thyrocytes. This result could have interesting clinical implications in view of the current interest in the anticancer use of NF-kB inhibitors. The mechanism by which TGF-b activates IkB degradation should be further studied. IL-1 degrades IkB through TAK1 activation (NinomiyaTsuji et al., 1999) , a kinase also activated by TGF-b.
To summarize our data, we propose a model of the contribution of TGF-b to the progression of thyroid hyperproliferative disease, in which TGF-b may have either of two opposing effects (apoptosis via p27 reduction, or survival via the NF-kB pathway). A third response to TGF-b, the antiproliferative response, is not altered in neoplastic human thyroid, thus explaining the low proliferative index of thyroid carcinoma. The apoptotic response to TGF-b is reduced or absent in neoplastic and metastatic thyrocytes (in line with the low apoptotic index observed in human thyroid carcinoma), because the p27 apoptotic program is overridden by the NF-kB survival program. Finally, in metastatic thyrocytes, TGF-b could be activating basal survival and migration-related genes. In this connection, a TGF-b antagonist has recently been reported to protect against metastasis (Muraoka et al., 2002; Yang et al., 2002) .
Materials and methods
Thyrocyte primary culture
The project had the approval of the Ethical Committee of the School of Medicine of the USC. To obtain the primary follicular cultures (Mothersill, 1995) , a portion of each thyroid specimen was dissected using a surgical blade and immersed in growth medium (Coon's modified Ham's F-12 medium supplemented with 5% NCS (Gibco BRL), 2 mM glutamine, a five-hormone mixture, 5 H (1 mIU/ml TSH, 10 ng/ml somatostatin, 10 mg/ml insulin, 1 nM hydrocortisone and 5 mg/ml transferrin) and 100 IU/ml penicillin, 100 mg/ml streptomycin and 2.5 ng/ml amphotericin B. The pathologist was very careful to exclude areas of fibrosis and take the portion from exactly the same point at which histopathological analysis would be conducted. The portions were digested in 1 mg/ml collagenase IV, 2.5 mg/ml trypsin in PBS for 1 h, then filtered through a 41-mm filter to remove undigested tissue fragments. Cells were washed several times and then seeded in growth medium. (Urbano et al., 2000) . Anti-TG immunofluorescence (1 : 65, Novocastra) was performed every two to three passages and cytoplasmic-stained cells counted.
The experiments were performed either in growth medium or in deprived medium (0.5% NCS without 5 H) for 2 days. 5 or 2 ng/ml hrTGF-b1 (Pharmacia) or vehicle was added to the medium. 50 mM of Z-VAD-FMK (Calbiochem) was added 1 h prior to TGF-b. 7.5 mM roscovitine (Sigma) was simultaneously added with TGF-b. 100 ng/ml of the peptide SN-50 (Calbiochem) was added 15 min before the TGF-b.
Immunoblotting
Total extracts were obtained as described (Carneiro et al., 1998) . Immunodetection was carried out with antibodies to PSmad2 (UBI), b-actin (Sigma), p27, cyclin D1, cyclin E and IkBa (Santa Cruz Biotechnology) at a 1 : 100 dilution. Western blotting of NIS (1 : 4000) and of TbRI and TbRII (1 : 100, Santa Cruz) was performed with 50 mg of membrane extracts (Levy et al., 1998) .
Proliferation assays
Cell number was assessed by the MTT assay (Carneiro et al., 1998) . Absorbance was measured at 550 nm. Alternatively, cells were counted in a Neubauer cytometer chamber. To supervise the permanence of the response to TGF-b, MTT assays were performed at each passage of the thyrocyte cultures. To monitor the arrest in G 1 induced by TGF-b, cells were fixed and stained with propidium iodide and analysed in a FACS Scan (Becton Dickinson). Thyrocytes did not lose the cell-cycle arrest response to TGF-b even after many passages.
Apoptosis assays
50 nM Hoechst 33258 and 1 : 250 annexin V-FITC (Becton Dickinson) plus 20 mM HEPES, pH 7.4, was added to the medium. After 45 min in the incubator, at least 200 cells/well were evaluated under the microscope with annexin V-FITC or Hoechst 33258 positivity taken to indicate early or late apoptotic events, respectively. DNA fragmentation was assayed by the ApoalertTM DNA fragmentation assay kit (Clontech) in 4% paraformaldehyde-fixed coverslides. 2 mg/ml TRITC-Phalloidin (Sigma) was added as a control of cellular morphology.
Kinase assay 100 mg of total proteins was incubated overnight at 41C with 1 mg anti-cdk2 antibody (Santa Cruz). Cdk2 activity was assayed as described (Carneiro et al., 1998) .
BrdU incorporation
After incubation for 48 h in deprived medium, the cells were labeled with 10 mM BrdU in DMEM þ /À2 ng/ml TGF-b for different times. The assay was carried out using the Biotrack TM kit (Pharmacia). Alternatively, coverslides were fixed overnight in ethanol, permeabilized in 4 M HCl, and incubated with 1 : 150 a-BrdU (Becton Dickinson), followed by 1 : 500 amouse-Cy2 (Jackson) plus DAPI.
Transient transfections
pRSV-b-gal, p3TP-Lux (bearing 3 Smad RE from the PAI-1 gene) or pNF-kB-luc (containing three tandemly repeated k B motifs of the Ig k gene upstream of a minimal IFN-promoter; Ninomiya-Tsuji et al., 1999) were transfected using FuGENE (Roche). PECE-ASp27 (Rivard et al., 1996; Ladha et al., 1998) , PECE empty vector, pFlag-p27 or pFlag empty vector were transfected in deprived medium. a-FLAG-FITC (Sigma) diluted in PBS þ 0.1% BSA was used at 1 : 100.
Statistical analysis
All the experiments were repeated at least three times with replication when possible. Results were compared with the nonparametric Mann-Whitney test.
Abbreviations NT, normal thyroid; GD, Grave's disease; MNG, multinodular goiter; FA, follicular adenoma; PC, papillary carcinoma; M, ganglion metastasis; CKI, cyclin-dependent kinase inhibitor.
